| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.7 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |